Jiangsu Hengrui Medicine (SHA:600276, HKG:1276) said 20 drugs have been included in the updated 2025 National Reimbursement Drug List of China, a Dec. 7 Hong Kong bourse filing said.
Shares of the drugmaker were down 1% in Monday afternoon trading.
Of the total, many drugs were added to the list for the first time, some were renewed, while newly added indications of other drugs were also included.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments